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important epidemiological and economic burden, literature on cost of chemother-
apy in breast cancer is rather scarce in Germany. The objective of this study was to
estimate the cost of adjuvant chemotherapy in early stage breast cancer in Ger-
many, using two different perspectives: the sick funds and the society. METHODS:
A semi-systematic search of the literature was conducted to identify relevant ar-
ticles describing the cost of adjuvant chemotherapy in Germany. The electronic
database Pubmed and a selection of congress databases were searched using com-
binations of search terms designed to identify publications describing cost of ad-
juvant chemotherapy in early stage breast cancer patients. Searches were limited
to those published in the English and German language between January 2000 and
April 2011. A retrospective multicentre study was conducted to collect chemother-
apy-related resources used. Unit costs were collected from public sources (EBM
catalogue, Rote list, DRG list). Cost items collected included: chemotherapy drugs,
monitoring and administration, prevention and management of adverse events,
transportation to the treatment centre, and when using the societal perspective,
also sick leaves. RESULTS: A total of 51 patients were included the study. The
following adjuvant chemotherapy regimens were given to the patients: TAC (22%),
FEC (20%), FECDOC (20%), TC (20%), ECDOC/PAC (12%) and others (8%). The
average total costs for an adjuvant chemotherapy treatment were estimated to be
€11,036 in a sick fund perspective and €16,199 in a broader societal perspective. The
direct costs were €5722 for chemotherapy drugs, €982 for chemotherapy adminis-
tration and monitoring, €4228 for supportive drugs and management of adverse
events. The indirect costs of sick leaves were €5163. CONCLUSIONS: Adjuvant
chemotherapy represents a significant economic burden to the health care system
and the society.
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OBJECTIVES: Oral oncologic therapies increasingly are becoming part of treatment
options for cancer. These agents often fall within the pharmacy benefit, with the
potential for increased out-of-pocket payments (OOPP) for patients. This study
evaluated patient OOPP for oral oncologic therapies in US managed care plans.
METHODS: Patients aged 18 years with 1 of 22 oral oncologics (altretamine, bex-
arotene, capecitabine, cyclophosphamide, dasatinib, erlotinib, etoposide, everoli-
mus, gefitinib, imatinib, isotretinoin, lapatinib, lenalidomide, leucovorin, nilotinib,
sorafenib, sunitinib, temozolomide, thalidomide, topotecan, tretinoin, vorinostat)
were identified in 2009 from a nationally-representative medical and pharmacy
claims database of over 100 US health plans. OOPP were calculated as the allowed
amount (dollars a health plan allows for a therapy, including member liability)
minus the paid amount (dollars paid by a health plan for a therapy). Mean/median
per-claim OOPP were reported for each oral therapy and stratified by geographic
region, health plan type, and payer type. RESULTS:A total of17,483 patients with at
least 1 oral oncologic were identified in 2009. Mean age was 38 years, 44% were
male, and 82% had a commercial payer. Per-claim OOPP for the 22 oral oncologics
varied. Median OOPP ranged from $0 (altretamine) to $42 (bexarotene); average
OOPP were $9 (leucovorin) to $523 (dasatinib). Overall, 79% of patients were paying
$50 or less per claim; 13% were paying $100 per claim. Among the majority of
therapies, the highest average OOPP were found in the Northeast and South. PPO
and indemnity plans had the largest OOPP for almost two-thirds of the therapies.
Medicare Risk (private Medicare) and self-insured patients had higher OOPP for
most therapies compared to commercial payers and Medicaid. CONCLUSIONS:
OOPP in the United States differ among oral oncologic options and confirm previ-
ous findings. As costs for therapy become a greater part of treatment decisions, an
understanding of the cost burden to patients will be critical in informing choices.
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OBJECTIVES: The major aims of the current research are to learn the average costs
of treatment of multiple myeloma (MM) in Ukraine. According to the world statis-
tics 30 new cases are registered annually per 1 million of population. In Ukraine
there are 4,434 cases of MM registered; these patients receive compensation by the
government for only limited amounts of necessary medicines, with most medi-
cines being paid for by patients themselves. METHODS: A database containing
records from hospital cards (2006-2010) for patients with MM was analyzed retro-
spectively. The sample was composed of 98 patients, aged 29 to 81 (mean age 62.5,
s.d. 9,6; 35.6% males). Drug costs related to direct diagnosis and associated MM
diseases (e.g., anemia, bone damage) were calculated. RESULTS: The average an-
nual cost of pharmaceutical treatment for patients with MM was 518.27EUR
(1EUR11,371UAH on 20.06.2011). Accounting for the prevalence of MM in Ukraine
(4,434 cases), the total cost of treatment of MM in Ukraine is 2,297,984EUR. A sig-
nificant amount of these costs covers treatment of MM-associated bone disease,
resulting in an average annual cost of 70.76EUR for treatment of these disorders of
MM patients. From basic therapy the most expensive were treatment schemes with
bortezomib (6 patients). If patients who were treated with bortezomib are excluded
from the general pool, the total costs of drug treatment will be 107.68EUR from
which 64.08EUR will take treatment of bone disorders with biphosphonates. No
correlations were found between sex, age, date of diagnosis and costs of treatment.
CONCLUSIONS: Analysis of the treatment practice and costs for MM patients has
shown that treatment of MM with bortezomib, even though involving only a small
number of patients, and treatment of MM-related conditions within the majority of
patients takes the major part of total costs.
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OBJECTIVES: To estimate the cost of treatment of oncological pain with four strong
opioids (methadone, morphine, oxycodone, fentanyl) in the Brazilian private
healthcare system between January and December 2010. METHODS: A claims da-
tabase of over 57 HMOs was analyzed to recover combined use of strong opioids
and oncological treatments between January and December 2010. Records showed
expenditure with medications, materials, hospitalization, and procedures and
diagnostics. RESULTS: Over the one-year study period, 293,918 patients made use
of at least one of the four opioids. The total healthcare expenditure with these
patients was R$ 3,243,890,302.91 (R$ 11,036.72/patient/year). Around 53% of these
patients (157,104) made concomitant use of oncology treatments, representing
around 74% of the total costs (R$ 2,424,503,643.76), with an average cost of R$
15,432.48/patient/year. The remaining patients (136,814) had an average cost of R$
5.989,06 per patient/year. Within the oncology patient population, the total health-
care expenditure with the four opioids alone was R$ 5,203,001.81. Fentanyl was the
most commonly used opioid in about 66% of patients, followed by morphine (33%),
methadone (1%) and oxicodone (0,8%). Around 17% of the oncology patient popu-
lation made use of two or more opioids during the study period. CONCLUSIONS:
Pain treatment of oncology patients is more costly for private payers in Brazil when
compared with patients not receiving oncological treatment. Although 47% of pa-
tients were considered non-oncological, this is not certain as they could have re-
ceived oncological treatment outside the study period or in a provider not covered
by the database (e.g. public hospital). With about 17% of oncological patients re-
ceiving two or more opioid treatments with the 12 month period suggests opioid
rotation is common.
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OBJECTIVES: Chemotherapy is vital for breast cancer treatment, but early-onset
toxicities like neutropenia hinder chemotherapy administration, especially in the
elderly. Neutropenia also increases costs due to hospitalizations and aggressive
systemic antibiotics administration. Primary prophylactic (PP) use of granulocyte-
colony stimulating factors (G-CSF) helps prevent neutropenia. However, evidence
supporting the cost-effectiveness of PPG-CSF is not conclusive and ASCO guide-
lines state the need for establishing cost-savings in high-risk groups like the el-
derly. This study examined the effect of PPG-CSF administration at the start of
first-course chemotherapy on Medicare costs during the year following the start of
chemotherapy. METHODS: A retrospective observational study of patients newly
diagnosed with breast cancer, between 1994 to 2002, was conducted using the
SEER-Medicare. To account for non-random nature of observational data, a cova-
riate genetic matching technique was used to pre-process the data before perform-
ing parametric regression analysis to estimate the effect of PPG-CSF on costs. Log-
arithm of cost was used as the dependent variable. RESULTS: Administration of
PPG-CSF during the first-course of chemotherapy was associated with 57% increase
in costs during the study period, despite an 11% drop in neutropenia hospitaliza-
tion costs. Forty-one percent of the increase in costs is due to increase in chemo-
therapy costs during the year after the start of chemotherapy. CONCLUSIONS: A
significant part of increase in immediate medical costs in breast cancer patients
receiving PPG-CSF is due to the improvement in chemotherapy administration.
Thus, increase in short-term costs are not necessarily bad in patients receiving
PPG-CSF. Adequate chemotherapy administration during the first year of breast
cancer therapy has long been established to prevent future recurrences, reduce
mortality and reduce long-term breast cancer care costs. Accounting for long-term
savings due to recurrence and metastasis prevention, indirect patient-care costs,
and quality of life aspects, is extremely vital for cost-analyses in chronic diseases
like breast cancer.
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OBJECTIVES: To estimate clinical outcomes and cost-offset (cost-benefit) from a
societal perspective expected from human papilloma virus (HPV) vaccination in
the Moscow region (MR). METHODS: A static population model developed in MS
Excel was adapted to the MR setting. The model estimated the annual number of
abnormal Papanicolaou smear test (abnormal PAP), precancerous lesions (cervical
intraepithelial neoplasia (CIN)) and cervical cancer (CC) as well as costs (RUB) as-
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sociated with treatment and productivity loss over a one year period at vaccine
steady state (i.e. when all women are vaccinated), current vs. future burden assum-
ing 95% vaccine coverage. The MR incidence data on abnormal PAP and CINs were
extrapolated from the relative proportion of abnormal PAP, precancerous lesions
and CC previously published. Vaccination effectiveness was based on clinical trial
data and HPV distribution for Russia and Eastern Europe. Medical costs were esti-
mated from resources used and listed Russian price. Indirect costs include unpaid
taxes, illness allowance and regional GDP foregone. No discount was applied. Sen-
sitivity analyses were conducted on main parameters (number of lesions, vaccine
effectiveness, costs). RESULTS: Vaccination with the bivalent HPV vaccine in the
MR was estimated to prevent 13,737 abnormal PAP (112.6 m.rub.), 11,750 CIN1 (296.1
m.rub.), 4,222 CIN2/3 (259.3 m.rub.), 504 CC (98.9 m.rub.), 199 cases of lifelong dis-
ability (44.6 m.rub.) and 276 cases of CC deaths annually. Total cost offsets could
amount to 811.6 m.rub. (664.8 m.rub. treatment cost only) representing 2.5x annual
cost of vaccinating one cohort of 12 year-old girls (328.9 m.rub.) (2.0x vs. treatment
cost only). The benefit-to-cost ratio (cost offset/vaccination cost) ranged from 1.8 to
3.1 over the sensitivity analyses. CONCLUSIONS: Implementation of HPV vaccina-
tion in the MR could significantly decrease cervical HPV-infection disease-related
burden. The cost of vaccination, at steady state, could be fully compensated by the
cost offset.
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OBJECTIVES:To investigate the extent to which using the most efficacious first-line
therapy to manage advanced non-small cell lung cancer (NSCLC) based on patients’
EGFR mutation status has clinical, economic, and quality of life (QoL) benefits from
diagnosis to death. METHODS: A deterministic cost-consequence model was de-
veloped to investigate alternative diagnostic and treatment strategies across mul-
tiple treatment lines in advanced NSCLC. Cost (drug and other treatment-related),
resource use, clinical, and QoL data were included. Cost and resource use data were
derived from the Dutch National Formulary, market research studies and expert
opinion. Clinical and QoL data – including progression-free survival (PFS) – were
derived from published studies and expert opinion. RESULTS:Different testing and
treatment strategies were modelled in a hypothetical population of 1,000,000 indi-
viduals. 498 patients presented with stage III/IV NSCLC. In the base-case (no EGFR
mutation testing) all patients received first-line doublet chemotherapy followed by
second-line docetaxel (50%) or best supportive care (50%). Total median PFS in the
population was 246.00 years (5.93 months per patient). Total healthcare costs, in-
cluding adverse event (AE) management, were €11,801,371 (€23,698 per patient).
EGFR mutation testing all patients identified 60 patients as EGFR mutation-posi-
tive. First-line treatments were assigned based on mutation status (EGFR muta-
tion-positive patients received gefitinib followed by second-line docetaxel, all oth-
ers were treated as in the base-case strategy). Compared with the base-case
strategy there was an 11.8% increase in total PFS (0.70 months per patient). Second-
line PFS increased 12.0%. Additionally, fewer AEs (anaemia, diarrhoea, dyspnoea,
febrile neutropenia, neurotoxicity and vomiting) and improved QoL were seen.
Excluding testing costs, total healthcare costs increased 17.4%. CONCLUSIONS:
Strategies where patients were appropriately treated based on EGFR mutation sta-
tus increased clinical and QoL benefits at relatively low incremental cost, com-
pared to strategies where patients were not tested or were treated sub-optimally.
Benefits extended beyond first-line treatment.
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OBJECTIVES: Two human papillomavirus (HPV) vaccines are available worldwide:
a bivalent vaccine (BV) targeting oncogenic high-risk HPV-16/18 and a quadrivalent
vaccine (QV) targeting both high-risk HPV-16/18 and low-risk HPV-6/11. Based on
data in their respective trials, BV is likely to have higher efficacy against non-
vaccine oncogenic HPV-types (cross protection). QV has an effect against genital
warts (GW). The potential effect of both vaccines in Thailand on cervical intraepi-
thelial neoplasia grade 1-3 (CIN1-3), GW, cervical cancer (CC) and related treatment
costs was investigated. METHODS: A static model estimated the above outcomes
over a one-year period at steady state versus the current situation. Costs were
assessed from a health care payer’s perspective. Epidemiological and cost data
were obtained from published sources; efficacy figures were based on the latest
clinical trial results from each vaccine and region-specific HPV distribution among
lesions (local data was used where possible). Sensitivity analyses were conducted
on all input data, such as with scenarios where the incidence and costs of treating
GW were varied. RESULTS: BV was projected to avert 9394 cases of CC annually. BV
potentially would result in an additional reduction of 5470 CIN1, 5177 CIN2/3 and
1113 CC cases annually compared with QV, while QV potentially would prevent an
additional 125,957 GW cases annually. The additional cost saved with BV was es-
timated at THB 356 million annually compared with QV. Sensitivity analyses report
additional cost-savings for the BV compared with QV under all scenarios.
CONCLUSIONS: The level of cross protection of BV potentially would allow for an
additional reduction in CC and HPV-related morbidity compared to QV; under our
model, this resulted in cost averted that offset the economic benefit QV will have in
preventing GW in Thailand.
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OBJECTIVES: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved
in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors
(pNET) that have spread or cannot be removed with surgery. This study evaluated
the cost-effectiveness of sunitinib  best supportive/palliative care (BSC) com-
pared to placebo  BSC in Portuguese patients. METHODS: A Markov model was
adapted to predict life-years (LY) and associated costs (€) of pNET patients’ treat-
ment over lifetime in Portugal. The model tracks transitions of patients between
three health states: progression free, post-progression and death. Transition prob-
abilities between health states and adverse events probabilities were based on
published results from the phase III pNET trial of sunitinib. BSC overall survival (OS)
probabilities were adjusted for crossover with a rank preserving structural failure
time (RPSFT) statistical analysis. Resource use was elicited through a panel of five
Portuguese experts with extensive clinical experience. Subsequent treatments are
not included given the lack of efficacy evidence. Adverse events treatment costs
and unit costs were extracted from Portuguese literature and official sources. A
National Health Service perspective was adopted and both costs and effectiveness
were discounted at 5%. RESULTS: Average cost per patient for sunitinib BSC and
placebo  BSC treatment were 54,215€ and 10,239€ respectively, while the average
effectiveness gained with sunitinib was 1.83LY. This resulted in an incremental
cost-effectiveness ratio (ICER) of 24,035€/LY. While the application of the RPSFT
method may have some limitations and therefore provide uncertainty regarding
the true OS benefit, the intent-to-treat classic analysis that does not correct for the
confounding effect of crossover generated an ICER of 34,387€/LY. CONCLUSIONS:
Compared with BSC, sunitinib treatment in patients with advanced or metastatic
unresectable pNET improve effectiveness in terms of life-years gained and is cost-
effective by the commonly used threshold in Portugal for assessment of new health
technologies.
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OBJECTIVES: To assess, from a UK NHS perspective, the cost-effectiveness of the
addition of rituximab (R) to selected chemotherapies: CVP (cyclophosphamide, vin-
cristine and prednisolone); CHOP (cyclophosphamide, doxorubicin, vincristine and
prednisolone) and MCP (mitoxantrone, chlorambucil and prednisolone) in the first-
line treatment of follicular lymphoma. METHODS: A patient level simulation
model was developed with four mutually exclusive and exhaustive health states:
progression free survival on first line treatment (the starting state); progression
free survival on second line treatment (PFS2); progression; and death (an absorbing
state). First-line treatment consisted of chemotherapy or R-chemotherapy. Pa-
tients relapsing before death move into PFS2 and are assumed to receive second-
line treatment dependent on initial treatment and time of relapse. After progres-
sion, patients enter the progression state where they reside until death. The model
horizon was 25 years with costs and benefits discounted at 3.5%. Separate analyses
were undertaken assuming rituximab maintenance for patients who responded to
R-chemotherapy in first-line induction. Evidence from phase III trial were used
when possible, however due to data limitations, assumptions were necessary
which increases the uncertainty in the results. RESULTS: The estimated Incremen-
tal Cost-Effectiveness Ratios (ICERs) for the addition of rituximab to CVP, CHOP and
MCP were £7,720, £10,834 and £9,316 per QALY gained respectively assuming no
first-line rituximab maintenance. The ICERs increased to £14,959, £21,687 and
£20,493 per QALY gained respectively when maintenance treatment was assumed.
The ICER was sensitive to assumptions regarding the choice of parametric distri-
bution to model the effectiveness of first-line treatment, the maximum time a
patient can remain progression-free and potential resistance to rituximab, with the
most favourable (unfavourable) ICER being approximately £4,000 (£61,000) per
QALY gained. CONCLUSIONS: The addition of rituximab to CVP, CHOP and MCP is
expected to fall below a cost per QALY gained of £25,000 regardless of the assump-
tion on maintenance.
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OBJECTIVES: The analysis of the sub-group of patients who received one prior
VEGF-TKI-based therapy in the RECORD-1 clinical trial reported a median progres-
sion-free survival of 5.42 months and 1.87 months for the everolimus and BSC-
alone arms, respectively. A Markov model was developed to assess the cost-effec-
tiveness of treating mRCC patients whose disease had failed on one prior VEGF-TKI
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